logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO 2020 – Pembrolizumab shows unprecedented promise in metastatic CRC subtype

The approximately doubled improvement in PFS is greater than any seen in previous mCRC therapies.